Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Condition: Basal Cell Carcinoma (BCC), First Line Treatment
NCT06981325
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: None
Stopped reason
Context when available
No stop reason available in the current public record.